Skip to content

Study · Observational study · n = 56 · 2026

8 results

Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study.

Miertová Z, Lecký P, Focko B, Bolek T, Péč MJ, Jurica J, Nagy N, Galajda P, Mokáň M, Samoš M

Scientific reports4 Jun 2026

PMID42236900 (opens in a new tab)PMCIDPMC13473473 (opens in a new tab)DOI10.1038/s41598-026-56147-8 (opens in a new tab)PepBankPUB-42236900
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In 56 adults with obesity, submaximal-dose semaglutide was followed by a mean weight loss of 6.45% at 3 months.

    In plain wordsIn 56 adults with obesity, people on lower-than-maximum semaglutide doses lost about 6.45% of body weight in 3 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight loss at 3 months
    Study

    n = 56

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    submaximal doses · 3 monthsAs given in this study (human).

    Measurements

    Weight loss
    6.45%
    3 months

    Source sentences

    Summary
    Our patients achieved a weight loss of 6.45 ± 0.31% (p < 0.01) in 3 months of semaglutide therapy
    1 context sentence
    Summary · context
    We carried out a prospective observational study investigating the effect of submaximal doses of semaglutide in 56 adult patients with obesity (mean age 49 ± 12 years, 42 female and 14 male).
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity, waist circumference decreased by 7 cm after 3 months of submaximal-dose semaglutide.

    In plain wordsIn adults with obesity, waist size fell by 7 cm after 3 months on lower-than-maximum semaglutide doses.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference decrease at 3 months
    Study

    n = 56

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    submaximal doses · 3 monthsAs given in this study (human).

    Measurements

    Waist circumference decrease
    7 cm
    3 months

    Source sentences

    Summary
    Regarding waist circumference, patients achieved a 7 cm decrease in waist circumference in 3 months, and an additional 6 cm at 6 months, respectively (p < 0.01).
    1 context sentence
    Summary · context
    We carried out a prospective observational study investigating the effect of submaximal doses of semaglutide in 56 adult patients with obesity (mean age 49 ± 12 years, 42 female and 14 male).
  3. 03HumanObservational studyEfficacy outcome

    In adults with obesity, the mean height/waist ratio decreased from 0.71 to 0.67 after 3 months of semaglutide.

    In plain wordsIn adults with obesity, the height/waist ratio went down after 3 months on lower-than-maximum semaglutide doses.

    Peptide
    Semaglutide
    Outcome
    DecreaseHeight/waist ratio at 3 months
    Study

    n = 56

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    submaximal doses · 3 monthsAs given in this study (human).

    Measurements

    Height/waist ratio baseline
    0.71 ratio
    baseline
    Height/waist ratio
    0.67 ratio
    3 months

    Source sentences

    Summary
    The mean height/waist ratio decreased from 0.71 ± 0.08 to 0.67 ± 0.09 after 3 months of treatment (p < 0.01) and to 0.63 ± 0.09 (p < 0.01) after 6-month of semaglutide treatment.
    1 context sentence
    Summary · context
    We carried out a prospective observational study investigating the effect of submaximal doses of semaglutide in 56 adult patients with obesity (mean age 49 ± 12 years, 42 female and 14 male).
  4. 04HumanObservational studyEfficacy outcome

    In adults with obesity, mean BMI decreased from 40.3 to 37.5 kg/m2 after 3 months of semaglutide.

    In plain wordsIn adults with obesity, body mass index went down after 3 months on lower-than-maximum semaglutide doses.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI at 3 months
    Study

    n = 56

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    submaximal doses · 3 monthsAs given in this study (human).

    Measurements

    BMI baseline
    40.3 kg/m2
    baseline
    BMI
    37.5 kg/m2
    3 months

    Source sentences

    Summary
    Mean BMI decreased from 40.3 ± 6.7 to 37.5 ± 6.83 kg/m2 (p 2 in the subgroup with 6 months of therapy (p < 0.01).
    1 context sentence
    Summary · context
    We carried out a prospective observational study investigating the effect of submaximal doses of semaglutide in 56 adult patients with obesity (mean age 49 ± 12 years, 42 female and 14 male).
  5. 05HumanObservational studyEfficacy outcome

    In a subgroup of 30 adults with obesity, submaximal-dose semaglutide for 6 months was followed by a mean weight loss of 11.35%.

    In plain wordsIn 30 adults with obesity, people on lower-than-maximum semaglutide doses lost about 11.35% of body weight in 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight loss at 6 months (subgroup)
    Study

    n = 30

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    submaximal doses · 6 monthsAs given in this study (human).

    Measurements

    Weight loss
    11.35%
    6 months

    Source sentences

    Summary
    in the subgroup of 30 patients where semaglutide was administered for 6 months, weight loss was 11.35 ± 0.47% (p < 0.01).
    1 context sentence
    Summary · context
    We carried out a prospective observational study investigating the effect of submaximal doses of semaglutide in 56 adult patients with obesity (mean age 49 ± 12 years, 42 female and 14 male).
  6. 06HumanObservational studyEfficacy outcome

    In adults with obesity, waist circumference decreased by a further 6 cm at 6 months of submaximal-dose semaglutide.

    In plain wordsIn adults with obesity, waist size fell by a further 6 cm at 6 months on lower-than-maximum semaglutide doses.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference decrease at 6 months
    Study

    n = 30

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    submaximal doses · 6 monthsAs given in this study (human).

    Measurements

    Additional waist circumference decrease
    6 cm
    6 months

    Source sentences

    Summary
    Regarding waist circumference, patients achieved a 7 cm decrease in waist circumference in 3 months, and an additional 6 cm at 6 months, respectively (p < 0.01).
    1 context sentence
    Summary · context
    We carried out a prospective observational study investigating the effect of submaximal doses of semaglutide in 56 adult patients with obesity (mean age 49 ± 12 years, 42 female and 14 male).
  7. 07HumanObservational studyEfficacy outcome

    In adults with obesity, the mean height/waist ratio decreased to 0.63 after 6 months of semaglutide.

    In plain wordsIn adults with obesity, the height/waist ratio went down further after 6 months on lower-than-maximum semaglutide doses.

    Peptide
    Semaglutide
    Outcome
    DecreaseHeight/waist ratio at 6 months
    Study

    n = 30

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    submaximal doses · 6 monthsAs given in this study (human).

    Measurements

    Height/waist ratio
    0.63 ratio
    6 months

    Source sentences

    Summary
    The mean height/waist ratio decreased from 0.71 ± 0.08 to 0.67 ± 0.09 after 3 months of treatment (p < 0.01) and to 0.63 ± 0.09 (p < 0.01) after 6-month of semaglutide treatment.
    1 context sentence
    Summary · context
    We carried out a prospective observational study investigating the effect of submaximal doses of semaglutide in 56 adult patients with obesity (mean age 49 ± 12 years, 42 female and 14 male).
  8. 08HumanObservational studyEfficacy outcome

    In a subgroup of adults with obesity, mean BMI decreased to 35.5 kg/m2 after 6 months of semaglutide.

    In plain wordsIn 30 adults with obesity, body mass index went down further after 6 months on lower-than-maximum semaglutide doses.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI at 6 months (subgroup)
    Study

    n = 30

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    submaximal doses · 6 monthsAs given in this study (human).

    Measurements

    BMI
    35.5 kg/m2
    6 months

    Source sentences

    Summary
    Mean BMI decreased from 40.3 ± 6.7 to 37.5 ± 6.83 kg/m2 (p 2 in the subgroup with 6 months of therapy (p < 0.01).
    1 context sentence
    Summary · context
    We carried out a prospective observational study investigating the effect of submaximal doses of semaglutide in 56 adult patients with obesity (mean age 49 ± 12 years, 42 female and 14 male).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.